NCT02052388View on ClinicalTrials.gov

Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections

PHASE2CompletedINTERVENTIONAL
Enrollment

215

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Skin InfectionBacterial Infection
Interventions
DRUG

Daptomycin

Active Comparator

DRUG

Brilacidin

Experimental Drug

Trial Locations (4)

89109

eStudy Site, Las Vegas

91911

eStudy Site, Chula Vista

91942

eStudy Site, La Mesa

92056

eStudy Site, Oceanside

Sponsors
All Listed Sponsors
lead

Cellceutix Corporation

INDUSTRY